Ryosuke Imai

Ryosuke Imai

Auto-generated profile, based on publicly available information

Ryosuke Imai

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, St Luke's International University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
RIRyosuke Imai
Ryosuke Imai
MOMasafumi Ono
Masafumi Ono
NNNaoki Nishimura
Naoki Nishimura
KSKoyu Suzuki
Koyu Suzuki
NKNobuyuki Komiyama
Nobuyuki Komiyama
TTTomohide Tamura
Tomohide Tamura

6 June 2025 in Chest
Verified
Journal Article
Open access
RIRyosuke Imai
Ryosuke Imai
RBRene S. Bermea
Rene S. Bermea
SZSophia H. Zhao
Sophia H. Zhao
SMSydney B. Montesi
Sydney B. Montesi
ASAnjali Singh
Anjali Singh
RHRobert Hallowell
Robert Hallowell
Identifying biomarkers is vital for interstitial lung disease (ILD) management and prognostication. While anti-Ro52 antibodies are frequently detected in autoimmune diseases, their significance in ILD remains unclear. What is the prognostic significance of anti-Ro52 positivity in patients with ILD? This retrospective cohort study used an ILD registry of patients seen at an academic tertiary hospital's ILD clinic between 2015 and 2024. All patients diagnosed with ILD and tested for anti-Ro52 antibody status were divided into anti-Ro52 positive (Anti-Ro52+) and negative (Anti-Ro52-) groups. The primary outcome was ILD progression or all-cause death. ILD progression was defined as any of the following: hospitalization due to ILD; absolute decline in forced vital capacity percent of predicted value ≥10% from baseline; or lung transplantation. Kaplan-Meier method and Cox proportional hazards regression model were used for survival analysis. Of 1,026 patients tested for the anti-Ro52 antibody (median age: 70 years; 52% male), 154 (15%) were Anti-Ro52+. Underlying ILD subtypes were as follows: interstitial pneumonia with autoimmune features (IPAF) (n = 489, 48%), connective tissue disease-ILD (n = 132, 13%), idiopathic pulmonary fibrosis (n = 103, 10%), hypersensitivity pneumonitis (n = 61, 6%), and other idiopathic ILD (n = 241, 24%). The Anti-Ro52+ group was younger (median age 67 vs. 70 years), was more likely to have CTD (28% vs. 10%) and more frequently had a copositive myositis-specific antibody (29% vs. 16%). After a median follow-up of 25.6 months, anti-Ro52+ subjects had a higher risk of ILD progression or death (hazard ratio 2.10; 95% CI, 1.61-2.73; P<0.001) and had a higher risk of lung transplant or death (hazard ratio 1.61; 95% CI, 1.11-2.35; P=0.014) on multivariable analysis. Anti-Ro52 seropositive ILD is associated with significantly worse progression-free and transplant-free survival and may inform disease prognostication and monitoring.

30 June 2021 in Multidisciplinary Respiratory Medicine
Verified
Journal Article
Open access
PDF file
SRShosei Ro
Shosei Ro
NNNaoki Nishimura
Naoki Nishimura
RIRyosuke Imai
Ryosuke Imai
YTYutaka Tomishima
Yutaka Tomishima
CSClara So
Clara So
TTTomohide Tamura
Tomohide Tamura
Background: Corticosteroids have been reported to reduce the mortality rates in patients with coronavirus disease 2019 (COVID-19). Additionally, the role of high-dose methylprednisolone pulse therapy in reducing mortality in critically ill patients has also been documented. The purpose of this study is to identify patients with COVID-19 who are suitable for methylprednisolone pulse therapy.Methods: This was a retrospective study that included patients with COVID-19 receiving methylprednisolone pulse therapy (>250 mg/day for 3 days) with subsequent tapering doses at our hospital between June 2020 and January 2021. We examined the differences in background clinical factors between the surviving group and the deceased group.Results: Of 156 patients that received steroid therapy, 17 received methylprednisolone pulse therapy. Ten patients recovered (surviving group) and seven patients died (deceased group). The median age of the surviving and deceased groups was 64.5 years (range, 57-85) and 79 years (73-90), respectively, with a significant difference (p=0.004). Five of the deceased patients (71%) had developed serious complications associated with the cause of death, including pneumothorax, pneumomediastinum, COVID-19-associated pulmonary aspergillosis, cytomegalovirus infection, and bacteremia. On the other hand, of the 10 survivors, only one elderly person had cytomegalovirus infection and the rest recovered without complications.Conclusion: Administration of methylprednisolone pulse therapy with subsequent tapering may be an effective treatment in patients with COVID-19 up to the age of early 70s; however, severe complications may be seen in elderly patients.

1 June 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
CSClara So
Clara So
RIRyosuke Imai
Ryosuke Imai
YTYutaka Tomishima
Yutaka Tomishima
NNNaoki Nishimura
Naoki Nishimura
We documented four cases of systemic lupus erythematosus (SLE) presenting with pleuritis as the initial disease manifestation. The diagnosis was challenging because, atypically, all patients were elderly and 3 of the 4 patients were men. Furthermore, SLE pleuritis, characterized by lymphocytic pleural effusion and high ADA activity, is difficult to differentiate from tuberculous pleurisy. A detailed physical examination, blood tests, and urinalysis are therefore indispensable to ensure an accurate diagnosis. We also reviewed the previously published case reports on SLE patients presenting with pleuritis and discussed the relevant findings.

19 September 2022 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
TNTomoaki Nakamura
Tomoaki Nakamura
RIRyosuke Imai
Ryosuke Imai
NNNaoki Nishimura
Naoki Nishimura
In this report, we present a case of nonsmall-cell lung cancer with anaphylaxis after 41 courses of pembrolizumab along with adrenal insufficiency as an immune-related adverse event (irAE). A 73-year-old man with no allergic disease started pembrolizumab for postoperative recurrence of lung cancer. After four courses, tumor shrinkage was observed and maintained thereafter. After the 39th course, his serum sodium level and random serum cortisol level decreased. Adrenal insufficiency was considered; however, the patient was asymptomatic. Furthermore, his serum sodium level improved spontaneously; therefore, he was followed up. At the end of the 40th course, rhinorrhea and pharyngeal discomfort were noted; however, they were mild and resolved spontaneously. Immediately after administration of the 41st course, he developed pembrolizumab-induced anaphylaxis with percutaneous oxygen saturation decreased. The symptoms quickly improved after intramuscular adrenaline were administered and did not recur. Three months after discharge, the patient was urgently examined for vomiting and anorexia. His serum sodium levels decreased to 119 mEq/L, and an adrenocorticotropic hormone stimulation test was performed. It showed a low response, and the patient was diagnosed with secondary adrenal insufficiency as an irAE of pembrolizumab and treated with hydrocortisone, which quickly improved his serum sodium levels and symptoms. When adrenal insufficiency develops due to irAEs, patients may be susceptible to allergic reactions.

19 September 2025 in Chest
Verified
Journal Article
Closed access
RIRyosuke Imai
Ryosuke Imai
SRShosei Ro
Shosei Ro
ATAnn-Marcia C. Tukpah
Ann-Marcia C. Tukpah
TSTakahiro Suzuki
Takahiro Suzuki
YKYuntae Kim
Yuntae Kim
SFSho Fukui
Sho Fukui